{"1": ["Article 1. Definitions", {}], "2": ["Article 2. Grant of Rights", {}], "3": ["2.1 Grant of Rights to Distributor", {}], "4": ["2.2 Sub-distribution by Distributor", {}], "5": ["2.3 Supply of Product for Distributorship", {}], "6": ["2.4 No Other Rights; Other Limitations", {}], "7": ["2.5 Non-Compete Covenant", {}], "8": ["2.6 No Activities Outside the Territory or Field", {}], "9": ["3.1 Joint Steering Committee", {}], "10": ["3.2 Expenses", {}], "11": ["3.3 Alliance Managers", {}], "12": ["3.4 Scope of Governance", {}], "13": ["4.1 Nonclinical and Clinical Studies and CMC Requirements", {}], "14": ["4.2 Regulatory Activities", {}], "15": ["4.3 Distributors Right to Use and Reference", {}], "16": ["4.4 Zogenixs Right to Use and Reference", {}], "17": ["4.5 Adverse Event Reporting", {}], "18": ["4.6 Drug Safety and Pharmacovigilance System including Global Safety Database", {}], "19": ["4.7 Regulatory Audit", {}], "20": ["4.8 Use of Subcontractors", {}], "21": ["4.9 Recalls", {}], "22": ["4.1 Development Expenses", {}], "23": ["5.1 Commercialization of the Product.", {}], "24": ["5.2 Supply", {}], "25": ["5.3 Trademark Rights", {}], "26": ["5.4 Commercial Expenses", {}], "27": ["6.1 Upfront Payment", {}], "28": ["6.2 Funding to Support Development of The Product", {}], "29": ["6.3 Regulatory Milestones", {}], "30": ["6.4 Sales Milestones", {}], "31": ["6.5 Supply Payments", {}], "32": ["7.1 Payment Method", {}], "33": ["7.2 Currency Conversion", {}], "34": ["7.3 Taxes", {}], "35": ["7.4 Records", {}], "36": ["7.5 Audits", {}], "37": ["7.6 Late Payments", {}], "38": ["8.1 Confidential Information", {}], "39": ["8.2 Exceptions", {}], "40": ["8.3 Permitted Disclosures", {}], "41": ["8.4 Confidentiality of this Agreement and its Terms", {}], "42": ["8.5 Public Announcements", {}], "43": ["8.6 Publication", {}], "44": ["8.7 Prior Non-Disclosure Agreements", {}], "45": ["8.8 Equitable Relief", {}], "46": ["9.1 Ownership of Intellectual Property", {}], "47": ["9.2 Zogenix Patent Prosecution and Maintenance", {}], "48": ["9.3 Infringement by Third Parties", {}], "49": ["9.4 Third Party Intellectual Property Rights", {}], "50": ["9.5 Patent Term Restoration", {}], "51": ["9.6 Patent Marking", {}], "52": ["9.7 Zogenix Trademarks", {}], "53": ["9.8 Product Trademarks", {}], "54": ["1 0.1 Mutual Representations, Warranties and Covenants", {}], "55": ["1 0.2 Representations, Warranties and Covenants of Distributor", {}], "56": ["1 0.3 Representations and Warranties of Zogenix", {}], "57": ["1 0.4 Disclaimer", {}], "58": ["1 0.5 Limitation of Liability", {}], "59": ["1 1.1 Indemnification of Zogenix", {}], "60": ["1 1.2 Indemnification of Distributor", {}], "61": ["1 1.3 Procedure", {}], "62": ["1 1.4 Insurance", {}], "63": ["1 2.1 Term", {}], "64": ["1 2.2 Termination", {}], "65": ["1 2.3 Rights on Termination", {}], "66": ["1 2.4 Exercise of Right to Terminate", {}], "67": ["1 2.5 Damages; Relief", {}], "68": ["1 2.6 Accrued Obligations; Survival", {}], "69": ["1 3.1 Objective", {}], "70": ["1 3.2 Resolution by Executives", {}], "71": ["1 3.3 Arbitration", {}], "72": ["1 4.1 Governing Law", {}], "73": ["1 4.2 Force Majeure", {}], "74": ["1 4.3 Assignment", {}], "75": ["1 4.4 Severability", {}], "76": ["1 4.5 Notices", {}], "77": ["1 4.6 Entire Agreement; Amendments", {}], "78": ["1 4.7 Headings", {}], "79": ["1 4.8 Independent Contractors", {}], "80": ["1 4.9 Waiver", {}], "81": ["1 4.1 Cumulative Remedies", {}], "82": ["1 4.11 Waiver of Rule of Construction", {}], "83": ["1 4.12 Interpretation", {}], "84": ["1 4.13 No Third Party Beneficiaries", {}], "85": ["1 4.14 English Language", {}], "86": ["1 4.15 Counterparts", {}], "87": ["1 4.16 Further Actions", {}]}